List of Juxtapid drug patents

Juxtapid is owned by Amryt.

Juxtapid contains Lomitapide Mesylate.

Juxtapid has a total of 8 drug patents out of which 0 drug patents have expired.

Juxtapid was authorised for market use on 21 December, 2012.

Juxtapid is available in capsule;oral dosage forms.

Juxtapid can be used as a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses, a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses.

The generics of Juxtapid are possible to be released after 19 August, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10555938 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(2 years from now)

US8618135 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(2 years from now)

US9265758 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 years from now)

US9364470 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 years from now)

US9433617 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 years from now)

US9861622 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 years from now)

US10016404 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(2 years from now)

US7932268 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Aug, 2027

(4 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in